Rhumbline Advisers Arcutis Biotherapeutics, Inc. Transaction History

Rhumbline Advisers

$104 Billion
Q1 2025

A detailed history of Rhumbline Advisers transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 181,074 shares of ARQT stock, worth $2.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

181,074

Previous 181,074 -0.0%

Holding current value

$2.64 Million

Previous $2.85 Million 0.6%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 08, 2025	BUY	$11.4 - $17.29 $148,450 - $225,150	13,022 Added 7.75%	181,074 $2.85 Million
Q4 2024 May 29, 2025	SELL	$8.31 - $14.99 $108,212 - $195,199	-13,022 Reduced 7.19%	168,052 $2.34 Million
Q4 2024 Jan 30, 2025	BUY	$8.31 - $14.99 $38,209 - $68,924	4,598 Added 2.81%	168,052 $2.34 Million
Q3 2024 Nov 12, 2024	SELL	$8.32 - $11.0 $31,907 - $42,185	-3,835 Reduced 2.29%	163,454 $1.52 Million
Q2 2024 Aug 01, 2024	BUY	$7.24 - $12.53 $303,761 - $525,708	41,956 Added 33.48%	167,289 $1.56 Million
Q1 2024 May 09, 2024	BUY	$3.25 - $11.77 $59,806 - $216,591	18,402 Added 17.21%	125,333 $1.24 Million
Q4 2023 Feb 08, 2024	BUY	$1.84 - $4.82 $50,601 - $132,554	27,501 Added 34.62%	106,931 $345,000
Q3 2023 Nov 09, 2023	BUY	$5.31 - $10.98 $4,662 - $9,640	878 Added 1.12%	79,430 $421,000
Q2 2023 Aug 08, 2023	BUY	$7.51 - $15.0 $183,138 - $365,790	24,386 Added 45.02%	78,552 $748,000
Q1 2023 May 11, 2023	BUY	$10.23 - $17.14 $8,071 - $13,523	789 Added 1.48%	54,166 $596,000
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $121,493 - $177,541	8,703 Added 19.48%	53,377 $790,000
Q3 2022 Nov 10, 2022	BUY	$17.85 - $26.95 $59,422 - $89,716	3,329 Added 8.05%	44,674 $854,000
Q2 2022 Aug 11, 2022	BUY	$16.33 - $22.2 $98,061 - $133,311	6,005 Added 16.99%	41,345 $881,000
Q1 2022 May 12, 2022	SELL	$14.38 - $22.79 $3,767 - $5,970	-262 Reduced 0.74%	35,340 $681,000
Q4 2021 Feb 10, 2022	BUY	$14.98 - $25.5 $269 - $459	18 Added 0.05%	35,602 $738,000
Q3 2021 Nov 12, 2021	BUY	$19.28 - $27.1 $25,064 - $35,230	1,300 Added 3.79%	35,584 $850,000
Q2 2021 Aug 05, 2021	BUY	$24.42 - $34.75 $345,567 - $491,747	14,151 Added 70.29%	34,284 $936,000
Q1 2021 May 06, 2021	BUY	$24.47 - $36.98 $1,101 - $1,664	45 Added 0.22%	20,133 $582,000
Q4 2020 Feb 10, 2021	BUY	$17.82 - $31.73 $55,473 - $98,775	3,113 Added 18.34%	20,088 $565,000
Q3 2020 Nov 12, 2020	BUY	$23.44 - $32.28 $139,327 - $191,872	5,944 Added 53.88%	16,975 $497,000
Q2 2020 Aug 13, 2020	BUY	$24.48 - $36.56 $28,152 - $42,044	1,150 Added 11.64%	11,031 $334,000
Q1 2020 May 06, 2020	BUY	$18.5 - $36.9 $182,798 - $364,608	9,881 New	9,881 $294,000

Others Institutions Holding ARQT

# of Institutions

249

Shares Held

126M

Call Options Held

605K

Put Options Held

170K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $878M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Arcutis Biotherapeutics, Inc. Transaction History